chrisvoncsefalvay/vaers-outcomes huggingface dataset:
1-2 minutes after IM GARDASIL, child became pale, diaphoretic, dizzy resolve 15 min; treatment: lying down.
Pt recvd 1st dose of Hep B vax 5APR91 & 2 hrs later pt exp severe abd cramps; sx lasted several hrs;
Headache; Injection site soreness; Injection site redness; A spontaneous report (United States) was received from a consumer, concerning himself, a 71-years-old male patient, who received Moderna's COVID-19 Vaccine and developed headache, injection site soreness and injection site redness.  The patient's medical history was not provided. Concomitant product use was not provided by the reporter.  On 17-Jan-2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (lot number 041L20A) intramuscularly for prophylaxis of COVID-19 infection.   On 17-Jan-2021 evening, the patient started having side effects. These side effects include headache, soreness and redness at the site of injection. On 18-Jan-2021, the patient was treated with acetaminophen 100mg and it helped him with his headache. However, he was still having soreness and redness at the site of injection. Patient also reported that he has not contacted his healthcare provider yet.  Action taken with mRNA-1273 in response to the events were not provided.   The outcome of the event, headache was considered resolved on an unspecified date in jan-2021. The outcome of the events, injection site soreness and injection site redness were considered not resolved at the time of this report.; Reporter's Comments: This case concerns a 71 year-old, male patient, who experienced events of  headache, injection site soreness and injection site redness. The events occurred the same evening after the first and last dose of mRNA-1273 vaccine administration. Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded and the events are assessed as possibly related.
received Shingrix on 30Jun2020/ not have a history of her getting the 2nd dose.; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 83-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 30th June 2020).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time of reporting, the patient did not receive the 2nd dose of Shingrix as per the vaccination schedule, which led to incomplete course of vaccination. The reporter consented to follow up.
Within one hour, I experienced overwhelming fatigue and exhaustion. Within a day or two of the shot, I began experiencing soreness and stiffness in my fingers, thumbs, toes, hips, elbows and wrists. Almost seven months post vax, I continue to have problems with exhaustion and joint pain.
Received Pfizer vaccine for first dose and Moderna vaccine for second; Arm pain; Fatigue; Headache; A spontaneous report was received from a nurse concerning a 49-year old, female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and experienced received Pfizer vaccine for first dose and Moderna vaccine for second, arm pain, fatigue, and headache.  The patient's medical history included intervertebral disc disorder. No relevant concomitant medications were reported.   On 08 Jan 2021, prior to the onset of the events arm pain and fatigue, the patient received a dose of mRNA-1273 (Lot number 25L20A)  intramuscularly for prophylaxis of COVID-19 infection.  On 21 Dec 2020, the patient received their first dose of the Pfizer vaccine.   On 08 Jan 2021, the patient was inadvertently administered a dose of the Moderna vaccine, and experienced some arm pain, fatigue, and headache. No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.  The event, received Pfizer vaccine for first dose and Moderna vaccine for second was considered resolved on 08 Jan 2021. The events, arm pain and fatigue, were considered resolved on 09 Jan 2021. The outcome of the event, headache, is unknown.; Reporter's Comments: This case concerns a 49-year old female patient with a medical history of intervertebral disc disease. The patient experienced Wrong product administered and non-serious listed events of Pain in extremity, Fatigue and Headache after receiving a dose of mRNA-1273 (Lot number 25L20A).   Based on temporal association between the use of the product and the onset of the events, a causal relationship cannot be excluded and the events are considered possibly related to the vaccine. Of note, patient's underlying intervertebral disc disease may have been contributory for the event of headache.
Strong heart palpitations for 4 hours night listed.  Constant fatigue across the next 2-3 weeks, chest pain for approximately 1 week following date of adverse event, slight pain in extremities for 3-4 weeks after adverse event , slight light headedness for 2-3 days after,
severe pain, random rotating pain; erythema; swelling in joints; hands, fingers, ankle, foot, knee, hip, mandibular joint, masseter; scalp tenderness; confusion; frequent urination for 10 days; headaches; Initial information received on 15-Oct-2019 regarding an unsolicited valid non-serious case received from a physician.  This case involves a 82 years old male patient who experienced severe pain, random rotating pain (pain), erythema (erythema), swelling in joints, hands, fingers, ankle, foot, knee, hip, mandibular joint, masseter (joint swelling), scalp tenderness (pain of skin), confusion (confusional state), frequent urination for 10 days (pollakiuria) and headaches (headache), while he received vaccine INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. At the time of the event, the patient had ongoing Food allergy (allergy to soy, peanuts, coffee and caffeine).  Concomitant medications included VARICELLA ZOSTER VACCINE RGE (CHO) (SHINGRIX) for Immunisation.  On 25-Sep-2019, the patient received a 0.5 ml dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE lot number not reported via intramuscular route in the left deltoid.  On an unknown date, the patient developed a non-serious severe pain, random rotating pain (pain), erythema, swelling in joints, hands, fingers, ankle, foot, knee, hip, mandibular joint, masseter (joint swelling), scalp tenderness (pain of skin), confusion (confusional state), frequent urination for 10 days (pollakiuria) and headaches (headache) (unknown latency) following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE.  Other relevant tests not reported.  Final diagnosis was pain, erythema, joint swelling, pain of skin, confusional state, pollakiuria and headache.  The patient was treated with Aleve and Benadryl.  The outcome was unknown for all the events.  Information on the batch number was requested.
This spontaneous report was received from pharmacist regarding a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On an unknown date, the patients were vaccinated with improperly stored doses of PNEUMOVAX 23 (lot # N004564, expiry date 22-OCT-2018) (dose and route not reported) for prophylaxis. The vaccine was exposed to temperature of 47 degrees Fahrenheit to 77 degrees Fahrenheit (49.1 Fahrenheit) for 1 hour and 45 minutes. No previous temperature excursion was reported. The call was not because of a data logger. No adverse effects and no product quality complaint (PQC) was reported. No further information provided. This is one of the several reports from the same reporter. Sender's Comments: US-009507513-1709USA000688: US-009507513-1708USA011699.
swelling, redness and hive reaction about 5 by 4 cm at vaccination site, new  systemic pruritis, itching, wheezing sensation without asthma
Dizzy, nauseated, felt hot. Brought to med screening via wheelchair for evaluation by medics. BP=114/76 Pulse=50 Left in stable condition at 17:13 p.m. Recorded by RN Medic
Patient received H1N1 nasal spray at clinic.  One hour after administration, pt reported sore throat and fever.  Patient was seen in our office on 12/12/09 with continued sore throat, fever, and body aches.  Throat culture was negative.  Patient was treated for mild ILI with rest and hydration.
admitted to hospital with respiratory failure, pneumonia, new infiltrates on chest x-ray, and diagnosis of COVID
Waited 15 minutes after - felt weird (light headed, nauseous) off and on Then left - Heart rate raised fast 70 to 140 Pulled over and went to hospital by ambulance  Diarrhea, nausea, flushed face, rapid heart rate  Recovered but has to wear a heart monitor for 4 days
This spontaneous report as received from a male consumer of unknown age refers to himself. On an unknown date the patient was vaccinated with ZOSTAVAX (lot # not reported) (strength and total daily dose not reported). He contracted the shingles after receiving ZOSTAVAX. It was unspecified whether the patient sought for medical attention. The outcome was unknown. Additional information is not expected.
Vertigo; Vomiting; A spontaneous report was received from a consumer concerning a 70-years-old  patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events vertigo, vomiting.  The patient's medical history was not provided. Concomitant medications reported were lisinopril, amlodipine, letrozole, zometa infusion, vitamin D3, balanced b50 tab, low dose bayer aspirin, calcium citrate for drug use for unknown indication.  On 4 Mar 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: 013A21A) via unknown route for prophylaxis of COVID-19 infection.  On 5 Mar 2021, the patient experienced the event(s) vertigo, vomiting.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.  On 6 Mar 2021 the outcome of event(s), vertigo, vomiting was resolved.
Information has been received from a nurse practitioner, for the Pregnancy Registry for GARDASIL, concerning a 16 year old female who on 01-SEP-2010 was vaccinated IM with a dose of GARDASIL (lot# 666121/1778Y) before the patient realized she was pregnant. The patient was vaccinated with a dose of Tdap and meningococcal vaccine (unspecified) most likely on the same day before she realized her pregnancy. The pregnancy test was conducted later in the day on 01-SEP-2010. The reporter reported no known adverse effect. The patient's last menstrual period was on 17-JUL-2010. Her estimated delivery date was 23-APR-2011. Ultrasound performed on 16-SEP-2010 and 06-DEC-2010. Obstetric bloodworks were normal. Follow-up information has been received from the nurse practitioner concerning the 16 year old female with no significant medical history, concurrent medical condition or previous pregnancy who on 01-SEP-2010 was vaccinated with a dose of GARDASIL. The patient became pregnant. The patient's last menstrual period was on 17-JUL-2010. Her estimated delivery date was 23-APR-2011. There was no complication during pregnancy. On 16-SEP-2010 ultrasound was performed to verify dates, which showed intrauterine pregnancy (IUP). On 11-NOV-2010, maternal serum alpha fetopreotein was tested with negative result. On 06-DEC-2010, ultrasound was performed for fetal assessment with normal result. On 18-APR-2011, at 39 gestation week, the patient delivered a normal, healthy female baby weighing 2945 grams via C-section due to failure to progress. The baby's Apgar score was 8/9. Upon internal overview, C-section/ failure to progress was determined to be an other important medical event. Additional information had been requested.
Subsequent to receiving second dose of varicella virus vaccine live the pt experienced continuous extreme fatigue and an unexplained fever one day per week which peaks at 4PM to 7PM. the pt sought unspecified medical treatment. Additional information had been requested.
Husband received SMPX vaccine 6/22/08 and kept covered; however small blister was under site not covered and may have touched site while sleeping 6/23/08.  On 6/24 noted 2 small red blisters to inner left upper arm (see pictures) that are similar to uncovered blister on husband.  Denied fever, n/v, chest pain, sob, itching.  Is not pregnant (tubes tied), no skin or cardiac history, no risk factors.  Has 3 children 6, 10, 12 not at home, one cat.  No paresthesia or left arm weakness, pain.  Symptoms: Lesions, papule.
Patient received vaccine on 10/06/15 at 3:50 pm. On 10/7/15 around 0930 she developed a rash on bilateral forearms, swelling of eyes and face. Went to ER for treatment where the ER said her Uvula was also swollen. They treated her with Solu-medrol and Pepcid.
Headache, chills, aches, slight fever - lasted a couple hours with aches lasting about 12 hours
This is my 3rd shot, my booster, required by my employer. I am a registered nurse for the past two years. I had only arm soreness with the first two vaccines, 7 hours after the booster I had significant body aches, took my routine night medications and tried to sleep, by morning had chills and rigors, thought my teeth would shatter too sick to get up for work, bone pain, body aches, dizziness when attempting to walk to the bathroom, every single bone in my body extreme pain 8/10 scale. I called in sick to the house supervisor, and he said he had a similar response. I was sick at home in severe pain two days, gradually felt better, tried to return to work and experienced manic symptoms, rushed speech, tremor, severe headaches, dizziness. We are so short staffed due to the nurses leaving who are anti-vaccine that I felt I could not leave. I continue to have headaches which are decreasing in severity daily, my strength is returning, was informed by Dr, our infectious disease specialist, that I should complete this form and notify you of my immune response to the booster. I also informed my family doctor . (See previous items)
Shingrix activated a severe episode of herpes 2 in me, resulting in symptoms identical to that of shingles: pain in hip area, raw nerve-endings, rash with extreme itching. Previous to the shot, I had not had a similar episode in over five years.
pt recv vax 9OCT97 on 13OCT was seen again for c/o marked swelling @ inj site & chills;pt seen again on 31OCT97 for c/o non-tender 1cm nodule @ inj site;advised Td rxn resolving & to return if does not resolve;c/o flu-like illness;
her husband was really sick; he is still weak from it; horrible diarrhea; vomiting; This is a spontaneous report from a contactable Consumer. A 84-years-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: EL1283), via an unspecified route of administration in right arm on 03Feb2021 (at 84-years age) as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The reporter confirms that her husband received no other vaccines on the same day as the COVID vaccine. On 04Feb2021, the patient received the first dose of the vaccine and experienced diarrhea and vomiting on. The reporter wants to know if the patient could get this after the second dose, too. The reporter also enquired if someone does not have side effects from the first dose, could they get them from the second dose and wants to know what would happen if she delayed her second dose. Two weeks after receiving the first dose patient had a very bad reaction. The reporter wants to know if her husband would experience the same if he received the second dose. The reporter states that her husband no longer has the vomiting and diarrhea, but he was still weak from it. The patient took Imodium AD, because he could not leave the house to see his doctor, because the diarrhea was so severe. The outcome of event diarrhea and vomiting was resolved on 14Feb2021, for weakness was not resolved and for illness was unknown.
Fever to 103 for 3 days. Morbilliform rash after fever; symptomatic care.
Patient received 2nd dose of Moderna in 2 weeks instead of 4 weeks.
Information has been received from a female consumer with a history of shingles who received a 0.65 ml dose of zoster vaccine live (Oka/Merck) and after administration she reported that she got shingles. She sought unspecified medical attention. A product quality complaint was not reported. No further information was available. This in follow-up to report (s) previously submitted on 12/21/2007. Follow up information from a physician indicated that the patient received the ZOSTAVAX vaccine (Merck) vaccination in April (year not specified), and claimed that she developed shingles one month later, though she was never examined at the medical care provider's office to confirm the diagnosis. The reporter was unaware that an adverse reaction has been reported. Current patient status was not reported. Additional information is not expected.
Had pain going down her back soon after getting High Dose flu shot - hurt all over gave her 1 Dose of EPI-PEN and symptoms subsided. Ambulance came to attend.
Per neurology consult: "Patient was at his baseline until when he received his 2nd dose of SARS-CoV-2 vaccination.  He complained of dyspnea and fear of impending doom after waking up the following morning with some disorientation.  He was found to be in AFib with RVR after it was brought to ER  the following morning  and the rhythm was converted to normal sinus rhythm.  Patient continues to have confusion after admission yesterday that seem to get worse today to the point where he did not know his own name or birthdate, and seemed to have global amnesia.  Patient has been more drowsy this afternoon after receiving lorazepam 1 mg IV for potential seizure activity so no reliable neurologic exam was obtained.  Patient remains afebrile with pulse ox in the low 90s on 4 L of supplemental nasal oxygen in the hospital.  He had moderate decrease in kidney function upon admission that has improved.  He has baseline anemia with hemoglobin at around 10. Incidentally patient had shingles in the right thoracic dermatome week ago for which he received valacyclovir.
Muscle contractions in my tights and major joint pains on my legs and arms. The pain in my joint was so overwhelming. My doctor prescribed a muscle relaxer and they took an xray of my shoulder, and asked to to physical therapy but I have a high deductible that I decided to do the exercise's at home.
started with numbness on tip of tongue and within a day to the side of my tongue. Next were my lips on the right side of my face were numb like a novicaine shot. This lasted for 3 more days and then on Friday Jan 15th 2010 I awoke with the right side of my face paralized. Went that day to emergency, had a CATH scan (sp) and it was determined that I had Bell's Palsey. For the next week things got worse. Breathing difficulty, weakness, light-head,drooling, could not close right eye completly extreme sensitivity to noise in right ear. For 6 days I could not move the muscles on the right side of my face. That is now possible but the numbness and sensitivity are still on that side of the face.
Got urticaria after 4 days when got Pfizer vaccination; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the right arm on 24Jul2021 at 16:30 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient previously received tetanus vaccine (MANUFACTURER UNKNOWN) and experienced allergy to vaccine (reported as allergies to tetanus needles). On 28Jul2021 at 16:30, 4 days after getting the Pfizer vaccination, the patient experienced urticaria. The event did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. Therapeutic measures were taken as a result of the event and included treatment with cetirizine (ZYRTEC). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event urticaria was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Patient developed mild tingling in the throat which lasted 24 hours but resolved and was not associated with any angioedema.  She had some transient joint discomfort.  Here menses arrived a few days early.  Approximately April 26th she developed supraclavicular/ paratracheal enlarged lymph nodes which would be worse in the early morning and late afternoon.  symptoms would radiate to her hear and cause discomfort with eating.
Itchy welts; 4-5 Welts; welts warm to touch; Swollen welts; Red welts in arm; Arm soreness at injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 67-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 15th October 2021, the patient received the 1st dose of Shingrix. On 15th October 2021, less than a day after receiving Shingrix, the patient experienced injection site pain. On 16th October 2021, the patient experienced welts, skin warm, swelling and erythema. On 17th October 2021, the patient experienced pruritus. On an unknown date, the outcome of the injection site pain was recovered/resolved and the outcome of the welts, skin warm, erythema and pruritus were not recovered/not resolved and the outcome of the swelling was recovering/resolving.   It was unknown if the reporter considered the injection site pain, welts, skin warm, swelling, erythema and pruritus to be related to Shingrix.   Additional details were reported as follows: The case was reported by the patient. Age at vaccination was not reported. The patient reported receiving 1st dose of Shingrix and experienced arm soreness (at the injection site) in the left arm on the same day.  The patient reported 4/5 welts formed on Saturday from the day of reporting approximately 3 inches below the injection site.  The patient said welts were approximately 6 by 4 inches in size, warm to the touch, swollen, itchy, and red.  The swelling seems to had decreased, but there has been no change in the other characteristics of the welts.  The itching did not begin until Sunday from the day of reporting.  All symptoms were approximately 3 inches below, not at, the injection site.  The only symptom experienced at injection site was soreness.  Redness from the welts had spread down the upper portion of the arm and into the inner arm. The reporter consented to follow up.
Patient has bilateral nodular lesions in the hands consistent with Dupuytren's contractures and less impressive lesions on the feet which suggest plantar fibromatosis.  He states his symptoms started after his 5th Anthrax vaccine, administered on 17 April 2003.  He denies any family hx of Dupuytren's.